Efficient nonviral transfection of dendritic cells and their use for in vivo immunization (original) (raw)

• Romani, N. et al. Proliferating dendritic cell progenitors in human blood. J. Exp. Med. 180, 83–93 ( 1994).
  Article CAS PubMed Google Scholar
• Nestle, F.O. et al. Vaccination of melanoma patients with peptide- or tumour lysate-pulsed dendritic cells. Nat. Med. 4, 328– 332 (1998).
  Article CAS PubMed Google Scholar
• Hsu, F.J. et al. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat. Med. 2, 52– 58 (1996).
  Article CAS PubMed Google Scholar
• Thurner, B. et al. Vaccination with MAGE-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J. Exp. Med 190, 1669–1678 (1999).
  Article CAS PubMed PubMed Central Google Scholar
• Nair, S.K. et al. Induction of primary carcinoembryonic antigen (CEA)-specific cytotoxic T lymphocytes in vitro using human dendritic cells transfected with RNA. Nat. Biotechnol. 16, 364–369 (1998).
  Article CAS PubMed Google Scholar
• Zhang, W. et al. Enhanced therapeutic efficacy of tumour RNA-pulsed dendritic cells after genetic modification with lymphotactin. Hum. Gene Ther. 10, 1151–1161 (1999).
  Article CAS PubMed Google Scholar
• Ludewig, B. et al. Immunotherapy with dendritic cells directed against tumour antigens shared with normal host cells results in severe autoimmune disease. J. Exp. Med. 191, 795–803 ( 2000).
  Article CAS PubMed PubMed Central Google Scholar
• Kaplan, J.M. et al. Induction of antitumour immunity with dendritic cells transduced with adenovirus vector-encoding endogenous tumour-associated antigens. J. Immunol. 163, 699–707 (1999).
  CAS PubMed Google Scholar
• Hung, K. et al. The central role of CD4+ T cells in the antitumour immune response . J. Exp. Med. 188, 2357– 2368 (1998).
  Article CAS PubMed PubMed Central Google Scholar
• De Veerman, M. et al. Retrovirally transduced bone marrow-derived dendritic cells require CD4+ T cell help to elicit protective and therapeutic antitumour immunity. J. Immunol. 162, 144– 151 (1999).
  CAS PubMed Google Scholar
• Kalams, S.A. & Walker, B.D. The critical need for CD4 T cell help in maintaining effective cytotoxic T lymphocyte responses . J. Exp. Med. 188, 2199– 2204 (1998).
  Article CAS PubMed PubMed Central Google Scholar
• Schnell, S., Young, J.W., Houghton, A.N. & Sadelain, M. Retrovirally transduced dendritic cells require CD4+ T cell help to elicit antitumour immunity: implications for clinical use of dendritic cells. J. Immunol. 164, 1243– 1250 (2000).
  Article CAS PubMed Google Scholar
• Arthur, J.F. et al. A comparison of gene transfer methods in human dendritic cells. Cancer Gene Ther. 4, 17–25 (1997).
  CAS PubMed Google Scholar
• Philip, R. et al. Transgene expression in dendritic cells to induce antigen-specific cytotoxic T cells in healthy donors. Cancer Gene Ther. 5, 236–246 (1998).
  CAS PubMed Google Scholar
• DiBrino M., Tsuchida, T., Turner, R.V., Coligan, J.E. & Biddison, W.E. HLA-A1 and HLA-A3 T cell epitopes derived from influenza virus proteins predicted from peptide binding motifs. J. Immunol. 151, 5930– 5935 (1993).
  CAS PubMed Google Scholar
• Lalvani. A. et al. Rapid effector function in CD8+ memory T cells. J. Exp. Med. 186, 859–865 (1997).
  Article CAS PubMed PubMed Central Google Scholar
• Taylor, P.M., Davey, J., Howland, K., Rothbard, J.B. & Askonas, B.A. Class I MHC molecules rather than other mouse genes dictate influenza epitope recognition by cytotoxic T cells. Immunogenetics 26, 267–272 (1987).
  Article CAS PubMed Google Scholar
• Bouchard, B., Del Marmol, V., Jackson, I.J., Cherif, D. & Dubertret, L. Molecular characterisation of a human tyrosinase-related protein-2 cDNA. Patterns of expression in melanocytic cells. Eur. J. Biochem. 219, 127– 134 (1994).
  Article CAS PubMed Google Scholar
• Okamoto, T. et al. Anti-tyrosinase-related protein-2 immune responses in vitiligo patients and melanoma patients receiving active specific immunotherapy. J. Invest. Dermatol. 111, 1034–1039 (1998).
  Article CAS PubMed Google Scholar
• Bloom, M.B. et al. Identification of tyrosinase-related protein 2 as a tumour rejection antigen for the B16 melanoma. J. Exp. Med. 185, 453–459 (1997).
  Article CAS PubMed PubMed Central Google Scholar
• Yang. Y., Li, Q., Ertl, H.C. & Wilson, J.M. Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenoviruses. J. Virol. 69, 2004–2015 (1995).
  CAS PubMed PubMed Central Google Scholar
• Jonuleit, H. et al. Efficient transduction of mature CD83+ dendritic cells using recombinant adenovirus suppressed T cell stimulatory capacity. Gene Ther. 7, 249–254 ( 2000).
  Article CAS PubMed Google Scholar
• Knight, S.C., Iqball, S., Roberts, M.S., Macatonia, S. & Bedford, P.A. Transfer of antigen between dendritic cells in the stimulation of primary T cell proliferation . Eur. J. Immunol. 28, 1636– 1644 (1998).
  Article CAS PubMed Google Scholar
• Tüting, T. et al. Dendritic cell-based genetic immunisation in mice with a recombinant adenovirus encoding murine TRP2 induces effective anti-melanoma immunity. J. Gene Med. 1, 400–406 (1999).
  Article PubMed Google Scholar
• Overwijk, W.W. et al. Vaccination with a recombinant vaccinia virus encoding a “self” antigen induces autoimmune vitiligo and tumour cell destruction in mice: requirement for CD4+ T lymphocytes. Proc. Natl. Acad. Sci. USA 96, 2982–2987 ( 1999).
  Article CAS PubMed Google Scholar
• Williams, S.G. et al. Repressor titration: a novel system for selection and stable maintenance of recombinant plasmids. Nucleic Acids Res. 26, 2120–2124 (1998).
  Article CAS PubMed PubMed Central Google Scholar
• Tüting, T., DeLeo, A.B., Lotze, M.T. & Storkus, W.J. Genetically modified bone marrow-derived dendritic cells expressing tumour-associated viral or “self” antigens induce antitumour immunity in vivo. Eur. J. Immunol. 27, 2702–2707 (1997).
  Article PubMed Google Scholar
• Felgner P.L. et al. Nomenclature for synthetic gene delivery systems. Hum. Gene Ther. 8, 511–512 ( 1997).
  Article CAS PubMed Google Scholar
• Morgan, S.M., Wilkinson, G.W., Floettmann, E., Blake, N. & Rickinson, A.B. A recombinant adenovirus expressing an Epstein–Barr virus (EBV) target antigen can selectively reactivate rare components of EBV cytotoxic T-lymphocyte memory in vitro. J. Virol. 70, 2394–2402 (1996).
  CAS PubMed PubMed Central Google Scholar
• Corico, R. et al. (eds.) Current Protocols in Immunology. (Wiley, New York, NY; 2000).
  Google Scholar